(0.22%) 5 142.75 points
(0.21%) 38 523 points
(0.30%) 17 899 points
(-0.57%) $83.37
(1.98%) $1.961
(-0.02%) $2 346.70
(0.24%) $27.60
(0.90%) $930.40
(-0.21%) $0.933
(-0.23%) $11.00
(-0.31%) $0.798
(1.07%) $92.86
0.68% $ 11.06
@ $11.35
Emitido: 14 feb 2024 @ 09:30
Retorno: -2.56%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
Volumen de hoy | 471 892 |
Volumen promedio | 829 517 |
Capitalización de mercado | 784.82M |
EPS | $0 ( 2024-03-06 ) |
Próxima fecha de ganancias | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.47 |
ATR14 | $0.0110 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.13 |
Last 97 transactions |
Buy: 9 826 125 | Sell: 711 798 |
Volumen Correlación
Zentalis Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas | |
---|---|
RAVN | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Zentalis Pharmaceuticals Correlación - Moneda/Commodity
Zentalis Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.43M (0.00 %) |
EPS: | $-4.18 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-5.65 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico